CETIEDIL CITRATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H31NO2S.C6H8O7
Molecular Weight	541.654
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.O=C(OCCN1CCCCCC1)C(C2CCCCC2)C3=CSC=C3

InChI

InChIKey=XMGJGSKRRWXOIF-UHFFFAOYSA-N

InChI=1S/C20H31NO2S.C6H8O7/c22-20(23-14-13-21-11-6-1-2-7-12-21)19(18-10-15-24-16-18)17-8-4-3-5-9-17;7-3(8)1-6(13,5(11)12)2-4(9)10/h10,15-17,19H,1-9,11-14H2;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula	C6H8O7
Molecular Weight	192.1235
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C20H31NO2S
Molecular Weight	349.531
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7159752 | https://www.ncbi.nlm.nih.gov/pubmed/11860149 | https://www.ncbi.nlm.nih.gov/pubmed/14729097 | https://www.ncbi.nlm.nih.gov/pubmed/11563923

Cetiedil is effective potassium channel blocker used as a peripheral vasodilator to treat patients with painful crises in sickle cell anemia and pain in the extremities caused by an arterial disease. Known pharmacological properties of the drug include vascular smooth muscle relaxation, inhibition of phosphodiesterase with the consequent increase in circulating cyclic AMP concentration, blockade of the effect of bradykinin and serotonin, analgesia, inhibition of platelet aggregation and the decrease of plasma and blood viscosity and plasma fibrinogen level. The antisickling effect of cetiedil is explained mainly in the light of the changes it induces in the activities of membrane-bound ATPases and the permeability properties of the erythrocyte membrane to cations and anions.

Approval Year

PubMed

Title	Date	PubMed
Synthesis and structure-activity relationships of cetiedil analogues as blockers of the Ca(2+)-activated K+ permeability of erythrocytes.	2001 Sep 27	11563923
An analysis of the mechanism by which cetiedil inhibits sickling.	2002 Jan 18	11860149
Inhibition of the antigen-induced activation of RBL-2H3 cells by cetiedil and some of its analogues.	2004 Jan 12	14729097
Inhibition of the antigen-induced activation of RBL-2H3 cells by charybdotoxin and cetiedil.	2004 Jan 12	14729096
Pharmacology of the human red cell voltage-dependent cation channel; Part I. Activation by clotrimazole and analogues.	2004 May-Jun	15121096

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:40:24 GMT 2023` Edited by `admin` on `Fri Dec 15 17:40:24 GMT 2023`
Record UNII	IE65P4OE02
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CETIEDIL CITRATE

Official Name

English

STRATENE

Brand Name

English

3-THIOPHENEACETIC ACID, .ALPHA.-CYCLOHEXYL-, 2-(HEXAHYDRO-1H-AZEPIN-1-YL)ETHYL ESTER, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1)

Common Name

English

VASOCET

Brand Name

English

CETIEDIL CITRATE [USAN]

Common Name

English

CELSIS

Brand Name

English

CETIEDIL CITRATE [MI]

Common Name

English

CETIEDIL CITRATE [MART.]

Common Name

English

2-(Hexahydro-1H-azepin-1-yl)ethyl α-cyclohexyl-3-thiopheneacetate citrate (1:1)

Systematic Name

English

Cetiedil citrate [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29707